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Abstract
Background: Drug resistance among tuberculosis patients in sub-Saharan Africa is increasing, possibly due to association
with HIV infection. We studied drug resistance and HIV infection in a representative sample of 533 smear-positive
tuberculosis patients diagnosed in Kampala, Uganda.
Methods/Principal Findings: Among 473 new patients, multidrug resistance was found in 5 (1.1%, 95% CI 0.3–2.5) and
resistance to any drug in 57 (12.1%, 9.3–15.3). Among 60 previously treated patients this was 7 (11.7%, 4.8–22.6) and 17
(28.3%; 17.5–41.4), respectively. Of 517 patients with HIV results, 165 (31.9%, 27.9–36.1) tested positive. Neither multidrug
(adjusted odds ratio (OR
adj) 0.7; 95% CI 0.19–2.6) nor any resistance (OR
adj 0.7; 0.43–1.3) was associated with HIV status.
Primary resistance to any drug was more common among patients who had worked in health care (OR
adj 3.5; 1.0–12.0).
Conclusion/Significance: Anti-tuberculosis drug resistance rates in Kampala are low and not associated with HIV infection,
but may be associated with exposure during health care.
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Introduction
An estimated 9.3 million incident tuberculosis (TB) cases and
1.4 million deaths occurred in 2007, making TB a major cause of
morbidity and mortality in the world. Of major concern to TB
control is the resistance to first-line anti-tuberculosis drugs. In
particular with multi-drug resistance (MDR), i.e resistance to
isoniazid and rifampicin, cure rates for first-line anti-TB drug
treatment are significantly reduced [1,2].
WHO estimates that 490,000 MDR-TB cases emerge every
year, representing 5.3% of all TB cases globally, resulting in
110,000 deaths [3]. Data on anti-TB drug resistance for sub-
Saharan Africa are often limited to hospital settings and
representative data based on quality-assured susceptibility testing
are scarce [2]. These data tend to show low MDR rates, but
concerns have been recently fuelled by an epidemic in Southern
Africa of MDR-TB, compounded by resistance to major second-
line drugs (extensively drug-resistant/XDR-TB), emerging against
a background of high HIV prevalence and expanding antiretro-
viral treatment [2,4].
HIV has a strong impact on TB incidence rates and HIV
infection has been associated with MDR-TB through outbreaks in
institutional settings [5]. Most studies however date from before
the large-scale roll-out of antiretroviral treatment (ART). Since
ART strongly reduces mortality in co-infected patients, it may
have a paradoxical effect of increased transmission of MDR-TB
through prolonged survival of infectious MDR-TB patients [6].
Results of the Uganda HIV sero-behavioral survey (2005) showed
an HIV prevalence of 8.5% for Kampala district and ART has
been widely rolled out in the district since 2004 (Kampala City
Council, unpublished data).
In the first anti-TB drug resistance survey in Uganda (1996–
1997), which used a similar sampling scheme as ours but covered
another area of the country, the prevalence of resistance to any
drugs was 19.8% and of MDR-TB 0.5% [7]. In a hospital-based
study conducted two years later in Kampala, MDR prevalence
was the same (0.5%), but resistance to rifampicin was 1.4%. More
recently a hospital based study in Kampala found 12.7% MDR
among previously treated patients [8]. Therefore data on anti-TB
drug resistance in Kampala was either outdated or hospital based
and no risk factors for anti-TB drug resistance were known.
To be able to estimate the current prevalence of anti-TB drug
resistance and risk factors associated with it in Kampala district,
we carried out a cross-sectional survey among new and previously
treated TB patients. We in particular wanted to establish whether
drug resistance prevalence among new cases had increased and/or
become associated with HIV status over the past 10 years during
which anti-retroviral treatment has been rolled out, increasing
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Control Programme un published data).
Methods
Ethical approval was obtained from the Research and Ethics
Committees of Makerere University College of Health Sciences,
Kampala. Written informed consent was obtained from all the
patients who participated in the study.
Study design
We conducted this survey between 18 August and 19 December
2008 in all health care facilities in Kampala that reported TB cases
to the National TB/Leprosy Programme (NTLP). This period was
determined by the sample size of 483 new patients, based on the
requirement to measure in this group an MDR prevalence of 1.4%
with an upper boundary of the 95% confidence interval of 3.0%.
Since all heath care facilities were included in the sample, we
assumed a design effect of 1. For logistical reasons we grouped the
facilities into three, based on the number of sputum smear-positive
patients expected in each group. Patient enrollment followed a
rotational fashion from one group of health facilities to another so
that each group participated for the same period in the study, thus
keeping a self weighted sample All sputum smear-positive patients
who were registered for treatment during the enrollment period
aged 18 years or above and consented to participate were enrolled.
Data collection
Each participant who consented to participate was requested to
provide two sputum samples (an early morning and spot) and a
blood sample for HIV testing. HIV testing was done within
24 hours of collection at a quality-assured laboratory, indepen-
dently of the routine HIV counseling and testing procedures.
Information about demographic characteristics, HIV status
prior to enrollment, use of anti-retroviral treatment and history of
TB treatment was collected through a structured interview. We
also obtained data about risk factors for anti-TB drug resistance
and HIV, including prison and health care exposure, injection
drug use and involvement in commercial sexual activities.
We defined a patient as previously treated if this patient had a
history of having taken first-line anti-tuberculosis drugs for one
month or more and as new if otherwise. Patient treatment history
was ascertained at the health facility using a standardized
questionnaire recommended by WHO [9].
We carried out re-interviews on 110 (20%) participants
randomly selected from the enrolled patients within 6 weeks of
the original interview to check for the quality of ascertainment of
treatment history. Re-interviews were conducted by staff who were
independent of the clinic where data was collected and blinded to
the original interview result; none showed any discrepancy in
treatment history classification to the original interviews.
Laboratory methods
Sputum culture. For each included patient the sputum
specimen with the highest bacillary count was decontaminated and
inoculated onto two slopes: one glycerol and the one pyruvate
Lo ¨wenstein-Jensen (L-J) medium incubated at 35–37uC and
examined weekly for growth up to 8 weeks. Cultures showing no
growth at 8 weeks were reported as negative. M. tuberculosis
identification was based on presumptive appearance of colonies on
culture and later confirmed by IS6110 based PCR. In addition,
when performing drug susceptibility testing, paraminobenzoic
Acid (PNB) 500 mg/ml was used to differentiate non-tuberculous
mycobacteria from M. tuberculosis.
Drug susceptibility testing (DST). All M. tuberculosis isolates
were tested at the National TB Reference Laboratory for
resistance to isoniazid, rifampicin, ethambutol and streptomycin
by the L-J proportion method using as concentrations 0.2 mg/ml
for isoniazid, 4 mg/ml for rifampicin, 40 mg/ml for ethambutol,
and 2.0 mg/ml for streptomycin. MDR was defined as resistance
of an isolate to at least isoniazid and rifampicin. Second line DST
was done on all MDR isolates using LJ proportional method using
critical concentrations 2.0 mg/ml for ofloxacin and 30.0 mg/ml for
kanamycin [10].
Drug susceptibility proficiency testing was performed at the
Supranational Reference Laboratory (SRL) in Borstel (Germany)
on all the identified MDR isolates, on 15 isolates randomly
selected from the remaining isolates of previously treated patients
and on all rifampicin-monoresistant isolates.
HIV Testing. HIV antibody testing was done in parallel
using Abbot Determine (Abbott Laboratories Abbott Park IL,
USA) and double-well run Vironostika HIV Uni-form II Ag/Ab
(BioMerieux Boxtel, Netherlands). The Generic Biorad HIV-1/
HIV-2 plus O-ELISA kit (Biorad Laboratories, Redmond WA,
USA) was used as the tie-breaker. All tests were performed in
accordance with the manufacturers’ instructions.
Data management
Data were double entered into Epidata 3.1 (www.epidta.dk).
Discrepancies were checked against the raw data. Analyses were
done in STATA v10 (Stata Corp. College Station TX, USA). For
comparison of categorical variables we used the X
2 test or the 2-
sided Fishers’ exact test as appropriate. Uni- and multivariable
analyses were done by logistic regression. Contribution of the
variables to the model was tested using the likelihood ratio X
2 test.
All significance testing was done at 5% confidence level.
Results
During the rotation periods, 633 sputum smear-positive TB
patients were registered with the NTLP of whom 557 (87.9%) were
enrolled after submission of 2 sputum samples. Most of the non
enrollments were due to declining participation and late start of
enrollment due to administrative problems in some of the
participating units. These did not significantly differ with regard to
demographic characteristics like age, sex or history of previous TB
treatment.Noneoftheculturesgrewnon-tuberculousmycobacteria.
Table 1 shows characteristics of the patients and proportions
with complete data.
Of the study participants 327 (58.7%) were male, the modal age
group was 25–34 years (216 participants, 38.8%), 50 (8.9%) were
45 years and above. There were 495 (88.9%) new and 62 (11.1%)
previously treated patients. Three hundred and seventeen (59.5%)
participants had been tested for HIV in the past; 91 (28.7%) were
known to be HIV-positive. Of these, 34 (37.4%) were on anti-
retroviral treatment; only one participant had used INH
prophylaxis before (table 1).
Out of the 557 smear-positive specimens received at NTRL,
those from 12 (2.2%) participants were contaminated and 12 (2.2%)
wereculture-negative.ThereforeDSTresults wereavailable for533
(95.6%) patients of whom 473 (88.7%) were new and 60 (11.3%)
previously treated (table 2). Of the latter the outcome of previous
treatment had been cure for 20, treatment completion with no
smear results for 16, failure for 7 and default for 17.
Among the new cases, MDR (percentage, 95% confidence
interval (CI)) was found in 5 (1.1; 0.3–2.5) and any drug resistance
in 57 (12.1, 9.3–15.3). Resistance among new cases was most
frequent to streptomycin (8.7%) and isoniazid (5.7%).
Anti-Tuberculosis Drug Resistance in Kampala
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MDR and 17 (28.3, 17.4–41.4) had any resistance. Of the 7 MDR
cases among this category, 3 (42.8%) were resistant to all four
drugs, 2 (28.6%) were additionally resistant to streptomycin and 2
(28.6%) were resistant to isoniazid and rifampicin only.
Among new and previously treated cases combined, 13.9%
(95% CI 11.0–17.1) had any resistance, 2.3% (95% CI 1.2–3.9)
had MDR, 9.3% (95% CI 7.0–12.2) had mono-resistance and
3.4% (95% CI 2.0–5.3) had poly-resistance. Specific resistance
patterns are shown in table 2.
Of the 30 samples submitted for external quality assessment,
susceptibility results were concordant for 28 (93.3%) of the isolates. All
resistant isolates were correctly detected, 2 isolates which were initially
monoresistant to rifampicin turned out pansensitive at retesting.
Of the 517 patients with HIV results 165 (31.9%, 95% CI 27.9–
36.1) tested positive. No association was established among new or
previously treated patients between any drug resistance and HIV
status, neither before (table 3) nor after adjustment for potential
confounders (table 4). Nor did we find any association between
MDR and HIV status, although numbers were too small to allow
meaningful multivariable analysis. We did not find significant
associations between any drug resistance or MDR and any of the
other demographic variables or potential risk factors for TB drug
resistance or HIV infection, including anti-retroviral treatment
among the HIV infected and history of hospitalization. We did
however find a significantly increased risk of any resistance among
new patients who had a history of having worked in health care
(adjusted odds ratio 3.5 95% CI 1.0–12.2; p=0.045). All 14
patients with a history of health care work had been tested for
HIV. Of the 4 who had any drug resistance, 2 (50%) were HIV-
infected, compared to 2 of 10 who had not (2-sided Fisher’s exact
p-value =0.520), while there was no increased prevalence of HIV
infection among patients with a history of health care work (4 of
10, 28.6%) compared to those without (161 of 503, 32.0%,
p.0.999). Two had monoresistance to streptomycin, one mono-
resistance to isoniazid, and one combined resistance to strepto-
mycin and isoniazid.
Discussion
This study shows low prevalence of anti-TB drug resistance in
Kampala district when new and previously treated patients are
Table 1. Characteristics of new and previously treated TB patients diagnosed in Kampala; August-December 2008.
PATIENT Characteristic Enrolled n=557 (%)**
Sex male 327 (58.7)
female 230 (41.3)
Age 18–24 183 (32.8)
25–34 216 (38.8)
35–44 108 (19.4)
45–54 37 (6.6)
.=55 13 (2.3)
Highest level of Education Non 36/557 (6.5)
Primary 228/557 (40.9)
Secondary 228/557 (40.9)
Higher learning 37/557 (6.6)
Unknown 4
Marital Status Single 216/557 (38.8)
Married 210/557 (37.7)
Separated 82/557 (14.7)
Widowed 23/557 (4.1)
Cohabiting 21/557 (3.8)
None of the above 5 (0.9)
Employment status Public Servant 34 (6.1)
Self employed 430 (77.2)
Peasant 41 (7.3)
Student 52 (9.3)
Residence Kampala 373 (67.0)
Outside Kampala 184 (33.0)
{HIV infection previously diagnosed positive Yes 96(16.6)
ART* use at enrolment Yes 34 (5.8)
Previous history of TB treatment Yes 62 (11.1)
No 495 (88.9)
**Column percentages.
{HIV= Human Immunodeficiency Virus.
*ART= Anti-Retroviral Therapy.
doi:10.1371/journal.pone.0016130.t001
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high as established in other studies in the region. Seven of the
twelve (58.3%) MDR cases were previously treated, yet this
category contributed only 11.3% of the study participants.
Although the MDR prevalence among new patients in this study
was similar to that in a number of other studies carried out in the
African region (1.4% in Burundi, 1.2% in Tanzania), it was lower
than in Gambia (2.6%), Mozambique (3.4%) and Rwanda (3.9%)
[11,12]. This suggests that transmission of MDR-TB in Kampala
is a limited problem. We found no association between any
resistance or MDR and HIV infection. Although the number of
MDR cases was small and thus limited the precision of our
estimate, a clinically or epidemiologically relevant effect of HIV on
the acquisition and/or transmission of MDR-TB would have
resulted in sizable MDR prevalence among HIV-infected patients,
which we did not observe.
The overall low MDR prevalence could result from community-
based TB care with fewer chances of MDR-TB and HIV infected
patients coming into close contact when seeking care in health
facilities. In settings with high HIV prevalence, MDR outbreaks
have been reported, generally resulting in increased anti-TB drug
resistance prevalence among HIV infected patients [13]. Lack of
association between drug resistance and HIV infection shows that
opportunities for (nosocomial) transmission of drug-resistant TB
may indeed be limited. In addition, supply of fixed dose
combinations free of charge by the NTLP may contribute to
patient adherence and prevent monotherapy during treatment.
Finally the Uganda NTLP uses for adult new TB patients, who
contribute about 80% of all the adult TB cases in Kampala, the
eight-month standard regimen in which rifampicin is only given in
the intensive phase. This regimen is likely to result in higher
relapse rates than the six-month regimen where rifampicin is used
Table 2. Anti-TB drug resistance among new and previously treated cases in Kampala; August-December 2008.
New cases(473)
Previously treated TB cases
(60) All cases
Pattern of resistance Number (%) 95% CI Number (%) 95% CI Number (%) 95% CI
Total Patients 473 (88.7) 60 (11.3) 533
Susceptible to all 416 (87.9) 84.7–90.6 43(71.6) 58.5–82.5 459 (86.1) 82.8–89
Any resistance* 57 (12.2) 9.2–15.3 17 (28.3) 17.4–41.4 74(13.9) 11.0–17.1
Any resistance to;
RMP 7 (1.5) 0.5–3.0 8 (13.3) 5.9–24 15 (2.8) 1.5–4.5
INH 27 (5.7) 3.8–8.2 12 (20) 10.7–32.0 39 (7.3) 5.2–9.8
EMB 3 (0.64) 0.13–1.8 6 (10) 3.7–20.5 9 (1.7) 0.7–3.1
SM 41 (8.7) 6.3–11.5 9 (15) 7–26.5 50 (9.4) 7–12.2
H+R Resistance (MDR**)
INH+RMP 4 (0.85) 0.23–2.1 2 (3.3) 0.4–11.5 6 (1.1) 0.4–2.4
INH+RMP+EMB 1(0.21) 0.54–11.7 1(1.7) 0.04–8.9 2(0.4) 0.04–13.5
INH+RMP+SM 0(0) - 2(3.3) 0.4–11.5 2 (0.4) 0.04–13.5
INH+RMP+EMB+SM 2 (3.3) 0.4–11.5 2 (0.4) 0.04–13.5
INH+ other resistance
INH+EMB 1 (0.21) 0.54–11.7 4 (6.7) 1.8–16 5 (0.94) 0.3–2.1
INH+SM 12 (2.5) 1.3–4.3 4 (6.7) 1.8–16 16 (3) 1.7–4.8
INH+EMB+SM 0(0) - 2 (3.3) 0.4–11.5 2 (0.4) 0.04–13.5
RMP+ other resistance
RMP+EMB 1 (0.21) 0.54–1.7 4 (6.7) 1.8–16.0 5 (0.94) 0.3–2.1
RMP+SM 2 (0.42) 0.05–1.5 5 (8.3) 2.7–18 7 (1.3) 0.5–2.6
RMP+EMB+SM 0(0) - 1(1.7) 0.04–8.7 1(0.2) 0.005–10
Monoresistance
{
RMP 0(0) - 0(0) - 0(0) -
INH 10 (2.12) 1.0–3.8 4 (6.7) 1.8–16 14 (2.6) 1.4–3.3
EMB 1 (0.21) 0.054–1.7 0(0) 0(0) 1 (0.19) 0.0004–0.010
SM 26 (12.9) 10–16 3(5) 1–13 29 (5.4) 3.6–7.7
Other resistance
{
EMB+SM 1 (0.21) 0.054–1.7 4 (6.7) 1.8–16 5 (0.94) 0.3–2.1
*Any resistance: resistance to the drug with or without resistance to other drugs.
RMP=rifampicin, INH=Isoniazid, SM=streptomycin, EMB= ethambutol.
CI = Confidence Interval.
**MDR: Multidrug resistance, i.e. resistance to at least INH and RMP.
{Monoresistance: resistance to only one anti-tuberculosis drug.
{Other resistance: Resistance to a combination of other drugs not including INH or RMP.
doi:10.1371/journal.pone.0016130.t002
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rifampicin to the first two months, potentially reducing the risk
of acquisition and hence transmission of MDR-TB in settings
where observation of drug intake is not consistently applied
throughout treatment.
Lack of association with HIV infection suggests that the recently
initiated large-scale introduction of ART in Kampala has not
resulted in paradoxical increases in rates of MDR-TB at the
population level. It may be that such effects will not occur, or that
they will only occur after prolonged large-scale use of ART, for
example, because it may require several TB transmission cycles
before an effect on MDR-TB transmission becomes apparent.
Therefore, continued combined TB-drug resistance and HIV
surveillanceremainsapriorityinsettingswhereTBandHIVcoexist.
Worth noting in our findings is the relatively high prevalence of
any resistance to streptomycin (15%) among previously treated
patients, because streptomycin is used during the first 2 months in
the standard retreatment regimen. Although NTLP is implement-
ing routine HAIN based rapid DST for previously treated patients,
the results are yet to be used in guiding treatment decisions.
Table 3. Univariable analysis for risk factors for any anti-TB drug resistance in Kampala.
Characteristic New patients Previously treated patients
n/N% OR; 95% CI P n/N (%) OR; 95% CI P
Sex
Males 29/278 (10.4) 1 0.200 14/37 (37.8) 1 0.045
Females 28/195 (14.4) 1.44 (0.83–2.51) 3/23 (13.0) 0.25 (0.06–0.98)
Age (years)
15–24 20/166 (12.1) 1 0.763 3/11 (27.3) 1 0.620
25–34 21/185 (11.4) 0.93 (0.49–1.79) 5/22 (22.7) 0.78 (0.15–4.12)
35–44 12/84 (14.3) 1.22 (0.56–2.63) 6/18 (33.3) 1.33 (0.26–6.94)
45–54 4/27 (14.8) 1.27 (0.40–4.05) 2/8(25) 0.89 (0.11–7.11)
$55 0/11 - 1/1
HIV infection status
Negative 40/308 (13.0) 1 0.444 14/44(31.8) 1 0.518
Positive 15/149 (10.1 0.75 (0.40–1.41) 3/16(18.8) 049 (0.12–2.02)
Worked in Health care
No 53/461 (11.5) 1 0.045 17/58 (29.3) 1
Yes 4/12 (33.3) 3.85 (1.12–13.2) 0/2 -
Admitted to hospital
No 50/422 (11.9) 1 0.652 12/42(28.6) 1 1.000
Yes 7/51 (13.7) 1.18 (0.51–2.77 5/18(27.8) 0.96 (0.28–3.29)
History of imprisonment
No 56/435 (12.9) 1 0.069 14/53 (26.4) 1 0.393
Yes 1/38 (2.6) 0.18 (0.02–1.36) 3/7 (42.9) 2.09 (0.41–10.5)
*See table 2 above for definitions.
doi:10.1371/journal.pone.0016130.t003
Table 4. Multivariate analysis for risk factors associated with any resistance to anti-TB drugs in Kampala.
NEW PATIENTS
Any resistance resistant Number (%) OR (95% CI) P-Value
HIV positive Yes 15/149 (10.1) 0.7 (0.4–1.3) 0.46
No 40/308 (13)
Worked in a health care
setting
Yes 4/12 (33.3) 3.5(1. –12) 0.045
No 53/461 (11.5)
Previously treated patients
Any resistance No 3/16 0.6 (0.12–2.9) 0.51
Yes 14/44
Other variables used for adjusting included age, sex, patient category, and marital status.
doi:10.1371/journal.pone.0016130.t004
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32% of the study participants (and 26.7% of the previously TB
treated participants) were HIV co-infected. However, TB/HIV
co-infection among the patients notified to the NTLP is above
50% of those who are tested (NTLP, unpublished data). In the
national referral hospital study mentioned earlier, the TB/HIV
co-infection prevalence among previously treated patients was
49% [8], substantially higher than what we found. This may be
due to a selection bias in the national surveillance data since not all
notified TB patients are tested for HIV. In addition, TB patients
diagnosed at the referral hospital may reflect a relatively ill
selection, and therefore may have an increased probability of HIV
infection. Finally, the wide roll-out of ART in Kampala to the
level of primary care facilities may increase the average CD4 levels
among the HIV infected, reducing the risk of progression from
latent TB infection to TB disease. Further studies are required to
Figure 1. Patient flow chart during the study. DST, Drug Susceptibility testing; ZN –ve, Ziehl Neelsen negative; LJ, Lowenstein Jensen; Culture
+ve, culture positive; Culture –ve, culture negative.
doi:10.1371/journal.pone.0016130.g001
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declined in this setting and others where ART is provided at a
large scale.
The association between transmitted anti-TB drug resistance
and a history of health care work calls for confirmation in other
studies since the numbers in this study were small: 4 patients with
history of health care work showed drug resistance (to isoniazid
and/to streptomycin) is cause for concern and calls for further
exploration. It may reflect prolonged infectiousness of drug
resistant cases due to delayed treatment response. This has been
shown for resistance to isoniazid when current first line regimens
are used, and may well occur in patients with streptomycin
resistance when treated with the standard retreatment regimen
[14]. As a result, health care workers could be more exposed to
drug-resistant than to drug-susceptible TB. E.g when working on a
TB ward or in another facility where TB patients on treatment are
encountered. HIV infection among these patients may also have
increased their risk of (re) infection and subsequent TB disease,
however we found no difference in HIV prevalence between
patients who did and patients who did not have history of health
care work, either with or without drug resistance. We did not find
HIV infection to be associated with having drug resistant TB
among these health care workers.
Limitations
This study had some limitations. The numbers of resistant cases,
in particular MDR, were small, limiting the power to detect risk
factors for drug resistance as statistically significant, including
associations with HIV infection. However, if anything, we
observed decreased risks of resistance among HIV-infected
patients making it unlikely that we missed positive associations of
substantial magnitude. While our sampling design in theory would
result in consecutive sampling of all the eligible patient population,
disrupted supply of anti-TB drugs during the survey, may have
affected the sampling since some sites did not enroll participants
into the study for the entire period. This could have led to selection
bias if this problem was more frequent in clinics with relatively
high resistance prevalence. For the same reason referral bias could
not be ruled out, since larger health units were prioritized when
anti-TB drug supplies were inadequate to cover all the TB
treatment facilities. This probably did not significantly affect our
results since health care facilities without drug supplies referred
patients to other health units, and all TB care centers in Kampala
were included in our study.
Anti-TB drug resistance prevalence in Kampala are low, but the
occurrence of primary MDR indicating transmission of resistant
M. tuberculosis strains is a threat to TB control in the district. We
therefore recommend that directly observed therapy for diagnosed
TB cases with drug-sensitive disease be strengthened to prevent
acquired drug resistance and a country-wide drug resistance
survey be carried out to establish the national burden. Establish-
ment of Programmatic Management of Drug-resistant TB in the
country is urgently required. The finding of health care work as a
risk factor for drug-resistant TB as well as the continuing risk of
outbreaks of (M)DR-TB among the HIV-infected call for
strengthening TB infection control in health care settings to
prevent nosocomial transmission. Routine DST of previously
treated patients should be strengthened in order to identify MDR
cases before treatment is started, since these have over 10%
probability of having MDR-TB. The introduction of rapid
resistance testing methods should be supported and treatment
policies adjusted so that treatment of previously treated TB cases
can be better guided by their resistance patterns.
Conclusion and recommendations
Prevalence of anti-TB drug resistance in Kampala is low and
not associated with HIV infection. Nonetheless continued and
expanded surveillance of anti-TB drug resistance should be a
priority. The association of drug resistance among new patients
with a history of work in health care suggests nosocomial
transmission and warrants further investigation.
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